2022
DOI: 10.1101/2022.02.12.480219
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

DNA-functionalized Gold Nanorods for Targeted Triple-modal Optical Imaging and Photothermal Therapy of Triple-negative Breast Cancer

Abstract: Targeted imaging and therapy for triple-negative breast cancer (TNBC) in the perioperative period are believed to be imperative for better disease management and improved life expectancy. Still, they are not yet available in clinical settings, and only a few nanoparticle-based theranostic agents potentially offer these capabilities. Herein, we develop an innovative class of biocompatible triple-modality nanoprobes (TMNPs) that offer optical imaging using optoacoustic, fluorescence, and surface-enhanced Raman s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 58 publications
0
2
0
Order By: Relevance
“…4 Silica-encapsulated DNA-modified AuNRs were employed to PTT of TNBC by targeting folate receptor 1, showing great promise for real-time multiplexed imaging and therapeutic capability. 5 However, there always exist minimal residual lesions in a deeper location with PTT alone, which can cause recurrence and metastasis of the cancers. 6 This problem has attracted great endeavors by combining photothermal agents with immunity inhibitors or immune adjuvants.…”
Section: ■ Introductionmentioning
confidence: 99%
“…4 Silica-encapsulated DNA-modified AuNRs were employed to PTT of TNBC by targeting folate receptor 1, showing great promise for real-time multiplexed imaging and therapeutic capability. 5 However, there always exist minimal residual lesions in a deeper location with PTT alone, which can cause recurrence and metastasis of the cancers. 6 This problem has attracted great endeavors by combining photothermal agents with immunity inhibitors or immune adjuvants.…”
Section: ■ Introductionmentioning
confidence: 99%
“…Moritz Kircher, unfortunately passed away during the preparation of the manuscript. An older version of this manuscript is available in a pre-print server …”
mentioning
confidence: 99%